| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 359 | 419 | 396 | 408 |
| Cost of Material Consumed | 102 | 112 | 111 | 117 |
| Change in Inventory | -2 | -2 | 2 | -0.2 |
| Gross Margins | 72.14 | 73.75 | 71.46 | 71.37 |
| Employee Benefit Expenses | 63 | 64 | 75 | 79 |
| Other Expenses | 113 | 143 | 135 | 141 |
| EBITDA | 83 | 102 | 73 | 71.2 |
| OPM | 23.12 | 24.34 | 18.43 | 17.45 |
| Other Income | 3 | 5 | 7 | 8.23 |
| Finance Cost | 2 | 2 | 1 | 0.3 |
| D&A | 22 | 23 | 24 | 26 |
| EBIT | 61 | 79 | 49 | 45.2 |
| EBIT Margins | 16.99 | 18.85 | 12.37 | 11.08 |
| PBT | 62 | 82 | 55 | 53 |
| PBT Margins | 17.27 | 19.57 | 13.89 | 12.99 |
| Tax | 18 | 25 | 11 | 14 |
| PAT | 44 | 57 | 44 | 39 |
| NPM | 12.26 | 13.6 | 11.11 | 9.56 |
| EPS | 4.4 | 5.7 | 4.4 | 3.9 |
| Financial Ratios | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Profit Margin | 23.12 | 24.34 | 18.43 | 17.45 |
| Net Profit Margin | 12.26 | 13.6 | 11.11 | 9.56 |
| Earning Per Share (Diluted) | 4.4 | 5.7 | 4.4 | 3.9 |
| Assets | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Fixed Assets | 340 | 328 | 347 | 343 |
| CWIP | 0 | 5 | 2 | 4.6 |
| Investments | 0 | 0 | 0 | 0 |
| Trade Receivables | 20 | 20 | 27 | 34 |
| Inventory | 11 | 13 | 11 | 11 |
| Other Assets | 93 | 134 | 121 | 140.4 |
| Total Assets | 464 | 500 | 508 | 533 |
| Liabilities | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Share Capital | 100 | 100 | 100 | 100 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 231 | 273 | 300 | 322 |
| Borrowings | 19 | 13 | 0 | 0 |
| Trade Payables | 33 | 34 | 33 | 39 |
| Other Liabilities | 81 | 80 | 75 | 73 |
| Total Liabilities | 464 | 500 | 508 | 533 |
| Cash-Flow Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| PBT | 59 | 82 | 55 | 53 |
| OPBWC | 87 | 114 | 74 | 74 |
| Change in Receivables | -56 | -29 | -13 | 2.9 |
| Change in Inventories | -2 | -2 | 2 | -0.2 |
| Change in Payables | 12 | -9 | 0 | 4.29 |
| Other Changes | 0 | 1 | 0 | 0.44 |
| Working Capital Change | -46 | -39 | -11 | 7.43 |
| Cash Generated From Operations | 41 | 75 | 63 | 81.43 |
| Tax | -10 | -20 | -19 | -13.12 |
| Cash Flow From Operations | 31 | 55 | 44 | 68.31 |
| Purchase of PPE | -26 | -9 | -46 | -22.6 |
| Sale of PPE | 1 | 0.1 | 0.5 | 0 |
| Cash Flow From Investment | -24 | -6.9 | -39 | -15.8 |
| Borrowing | -18 | -6 | -13 | 0 |
| Dividend | -5 | -15 | -17 | -17 |
| Equity | 0 | 0 | 0 | 0 |
| Others From Financing | -3 | -2 | -2 | -1 |
| Cash Flow from Financing | -26 | -23 | -32 | -18 |
| Net Cash Generated | -19 | 25.1 | -27 | 34.51 |
| Cash at the Start | 31 | 12 | 37 | 9.93 |
| Cash at the End | 12 | 37.1 | 10 | 44.44 |
Lakeshore Hospital and Research Centre Limited, popularly known as Lakeshore Hospital, is one of Kerala’s leading multi-specialty healthcare institutions, renowned for its advanced medical infrastructure and comprehensive clinical services. Located in Kochi, the hospital has earned a strong reputation for excellence in specialties such as oncology, cardiology, gastroenterology, orthopaedics, and transplant medicine. Over the years, Lakeshore has positioned itself as a trusted healthcare destination for patients across India and abroad, benefiting from medical tourism and the increasing demand for high-quality tertiary care. Its growing brand value and expansion plans contribute to the rising investor interest in the company’s unlisted shares.
The hospital has continually expanded its facilities, upgraded its medical technology, and enhanced its patient-centric care model. With modern diagnostic centres, advanced ICUs, world-class operation theatres, and a strong team of specialist doctors, Lakeshore ensures high-quality, outcomes-driven healthcare delivery. In recent years, strategic investments in oncology, critical care, and robotic surgery have strengthened its clinical leadership. The hospital’s strong occupancy rates, diversified revenue mix, and increasing inflow of international patients highlight its stable operational performance. This continuous improvement in infrastructure and service offerings adds to its attractiveness as a long-term healthcare asset.
From an investment viewpoint, Lakeshore Hospital’s unlisted shares provide exposure to India’s fast-growing private healthcare sector, which is witnessing rising demand due to lifestyle changes, increased health awareness, and gaps in public healthcare infrastructure. The hospital’s strong brand equity, expansion-focused strategy, and robust patient inflow make it a compelling player in this segment. However, investors should also consider factors such as regulatory requirements, competitive pressures from other hospital chains, and capital-intensive expansion cycles. Despite these considerations, Lakeshore Hospital stands out as a well-managed healthcare institution with long-term growth potential, making its unlisted shares an interesting option for investors looking at stable, asset-backed healthcare investments.
Q:1 How can I book Lakeshore Hospital Unlisted Shares?
Answer: You can confirm the booking of Lakeshore Hospital Unlisted Shares with us at a trading price.
Q:2 What documents do I need to provide for purchasing Lakeshore Hospital Unlisted Shares?Answer: You need to provide your client master report, PAN Card, and a Cancelled Cheque if you are not transferring funds from the bank account mentioned in the CMR Copy.These are KYC documents required as per SEBI regulations.
Q:3 How will I receive the bank details for the fund transfer?
Answer: We will provide you with the bank details after you confirm your booking.
Q:4 What payment methods are accepted for buying Lakeshore Hospital Unlisted Shares?Answer: Payment can be made through RTGS, NEFT, IMPS, or Cheque Transfer.Please note that cash deposits are not accepted.
Q:5 From which bank account should I make the payment?
Answer: Payment must be made from the same bank account where the shares will be credited.
Q:6 Is there a specific time frame for making the payment after booking the shares?Answer: While the specific time frame may vary, it is advisable to make the payment promptly to ensure a smooth transaction.Please check with us for any time-related guidelines.
Q:7 What happens if I do not have a client master report?
Answer: If you do not have a client master report, you should ask your broker for it, as it is a necessary document for the transaction.
Q:8 Why are KYC documents required for purchasing shares?Answer: KYC documents are required as per SEBI regulations to verify the identity of the investor and ensure compliance with legal requirements.